Nesreen S. Ismail

1.7k citations

19 papers · 1.4k indexed · 1 hit paper · h-index 10

Cardiology and Cardiovascular Medicine top 5%
- Lipid metabolism and disorders 2
Oncology top 5%
- CAR-T cell therapy research 6
Hematology top 10%
Gastroenterology top 10%
Cancer Research
- Cancer, Hypoxia, and Metabolism 4
Molecular Biology
- Angiogenesis and VEGF in Cancer 6
Biotechnology
- Cancer Research and Treatments 5
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 4
Surgery
- Tissue Engineering and Regenerative Medicine 2
Immunology
- Immunotherapy and Immune Responses 2

Co-authors: Susan M. Dallabrida Maria A. Rupnick Elke Pravda Flávia Cassiola David Zurakowski David M. Harris Frederick J. Schöen Jey-Hsin Chen
Cited by: Cardiology and Cardiovascular Medicine Oncology Hematology
Partner nations: United States Canada

In The Last Decade

Nesreen S. Ismail

18 papers receiving 1.4k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Nesreen S. Ismail

Since Specialization

Citations

This map shows the geographic impact of Nesreen S. Ismail's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nesreen S. Ismail with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nesreen S. Ismail more than expected).

Fields of papers citing papers by Nesreen S. Ismail

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nesreen S. Ismail. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nesreen S. Ismail. The network helps show where Nesreen S. Ismail may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Nesreen S. Ismail, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Nesreen S. Ismail Line = papers co-authored together Nesreen S. Ismail links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work
1	Abstract 2054: WTX-124 is a novel IL-2 pro-drug that is conditionally activated in tumors and drives anti-tumor immunity by activating tumor infiltrating CD8+ T cells Christopher J. Nirschl,Heather R. Brodkin,Daniel J. Hicklin,Nesreen S. Ismail,Kristin Morris,Andrés Salmerón,Cynthia Seidel‐Dugan,Philipp Steiner,Zoe Steuert,Jenna M. Sullivan,William M. Winston	2022	0
2	723 WTX-613, a conditionally activated IFNα INDUKINE™ molecule, induces anti-tumor immune responses resulting in strong tumor growth control in syngeneic mouse tumor models Ethika Tyagi,Heather R. Brodkin,Josue Canales,Dan Hicklin,Nesreen S. Ismail,Kristin Morris,Christopher J. Nirschl,Andrés Salmerón,Cindy Seidel-Dugan,Philipp Steiner,Zoe Steuert,Jenna M. Sullivan,William M. Winston	2021	3
3	Abstract 1716: WTX-330, a conditionally activated IL-12 INDUKINE, releases IL-12 selectively in the tumor microenvironment to activate anti-tumor immune responses and induce regressions in mouse tumor models Philipp Steiner,Heather R. Brodkin,Dan Hicklin,Nesreen S. Ismail,Kristin Morris,Christopher J. Nirschl,Andrés Salmerón,Cindy Seidel-Dugan,Zoe Steuert,Jenna M. Sullivan,William M. Winston	2021	4
4	Conditionally Activated IL-12 or IFNα Indukine™ Molecules Inhibit Syngeneic Lymphoma Tumor Growth in Mice, Induce Anti-Tumor Immune Responses and Are Tolerated in Non-Human Primates Philipp Steiner,Heather R. Brodkin,Josue Canales,Daniel J. Hicklin,Randi Isaacs,Nesreen S. Ismail,Kristin Morris,Christopher J. Nirschl,Andrés Salmerón,Cindy Seidel-Dugan,Zoe Steuert,Jenna M. Sullivan,Ethika Tyagi,William M. Winston	2021	9
5	715 WTX-330 is an IL-12 pro-drug that is conditionally activated within the tumor microenvironment and induces regressions in mouse tumor models Kristin Morris,Heather R. Brodkin,Daniel J. Hicklin,Nesreen S. Ismail,Christopher J. Nirschl,Andrés Salmerón,Philipp Steiner,Zoe Steuert,Jenna M. Sullivan,William M. Winston	2021	2
6	Abstract 1723: WTX-124 is an IL-2 pro-drug conditionally activated in tumors and able to induce complete regressions in mouse tumor models Andrés Salmerón,Heather R. Brodkin,Daniel J. Hicklin,Nesreen S. Ismail,Kristin Morris,Christopher J. Nirschl,Cynthia Seidel‐Dugan,Philipp Steiner,Zoe Steuert,Jenna M. Sullivan,William M. Winston	2021	1
7	718 WTX-124 is a novel IL-2 pro-drug that is conditionally activated in tumors and drives antitumor immunity in murine syngeneic cancer models Christopher J. Nirschl,Heather R. Brodkin,Daniel J. Hicklin,Nesreen S. Ismail,Kristin Morris,Andrés Salmerón,Cindy Seidel-Dugan,Philipp Steiner,Zoe Steuert,Jenna M. Sullivan,William M. Winston	2021	3
8	Abstract 1153: Effective treatment of cancer associated cachexia by AV-380, a GDF15 inhibitory antibody Lorena Lerner,Nianjun Tao,Brian Krieger,Richard Nicoletti,Bin Feng,Nesreen S. Ismail,William M. Winston,Yanyu Zhang,Jinwei Jiang,Solly Weiler,Jenő Gyuris	2015	4
9	QHREDGS Enhances Tube Formation, Metabolism and Survival of Endothelial Cells in Collagen-Chitosan Hydrogels Jason W. Miklas,Susan M. Dallabrida,Lewis A. Reis,Nesreen S. Ismail,Maria A. Rupnick,Milica Radisic	2013	38
10	Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition Sarah B. Sunshine,Susan M. Dallabrida,Ellen M. Durand,Nesreen S. Ismail,Lauren Bazinet,Amy E. Birsner,Regina Sohn,Sadakatsu Ikeda,William T. Pu,Matthew H. Kulke,Kashi Javaherian,David Zurakowski,Judah Folkman,Maria A. Rupnick	2012	40
11	Contrary Effects of the Receptor Tyrosine Kinase Inhibitor Vandetanib on Constitutive and Flow-Stimulated Nitric Oxide Elaboration in Humans Erik Mayer,Susan M. Dallabrida,Maria A. Rupnick,Whitney Redline,Keri Hannagan,Nesreen S. Ismail,Harold J. Burstein,Joshua A. Beckman	2011	39
12	GP369, an FGFR2-IIIb–Specific Antibody, Exhibits Potent Antitumor Activity against Human Cancers Driven by Activated FGFR2 Signaling Ailin Bai,Kristan Meetze,Nhi Vo,Sriram Kollipara,Elizabeth K. Mazsa,William M. Winston,Solly Weiler,Laura L. Poling,Ting Chen,Nesreen S. Ismail,Jinwei Jiang,Lorena Lerner,Jenő Gyuris,Zhigang Weng	2010	123
13	Photocrosslinkable chitosan modified with angiopoietin‐1 peptide, QHREDGS, promotes survival of neonatal rat heart cells Fiona Rask,Susan M. Dallabrida,Nesreen S. Ismail,Zohreh Amoozgar,Yoon Yeo,Maria A. Rupnick,Milica Radisic	2010	37
14	Angiopoietin-1 Reduces H2O2-Induced Increases in Reactive Oxygen Species and Oxidative Damage to Skin Cells Nesreen S. Ismail,Elke Pravda,Dan Li,Shou‐Ching Shih,Susan M. Dallabrida	2010	21
15	Hydrogels modified with QHREDGS peptide support cardiomyocyte survival in vitro and after sub-cutaneous implantation Fiona Rask,Anton Mihic,Lewis A. Reis,Susan M. Dallabrida,Nesreen S. Ismail,Krista L. Sider,Craig A. Simmons,Maria A. Rupnick,Richard D. Weisel,Ren‐Ke Li,Milica Radisic	2010	26
16	Integrin binding angiopoietin‐1 monomers reduce cardiac hypertrophy Susan M. Dallabrida,Nesreen S. Ismail,Elke Pravda,Emily M. Parodi,Renée Dickie,Ellen M. Durand,Jean Luc Laı̈,Flávia Cassiola,Rick A. Rogers,Maria A. Rupnick	2008	39
17	Cardiotoxicity associated with tyrosine kinase inhibitor sunitinibbreakdown → Tammy F. Chu,Maria A. Rupnick,Risto Kerkelä,Susan M. Dallabrida,David Zurakowski,Lisa Nguyen,Kathleen C. Woulfe,Elke Pravda,Flávia Cassiola,Jayesh Desai,Suzanne George,David M. Harris,Nesreen S. Ismail,Jey-Hsin Chen,Frederick J. Schöen,Annick D. Van den Abbeele,George D. Demetri,Thomas Force,Ming Hui Chen,Jeffrey A. Morgan	2007	814
18	Abstract 1505: Sunitinib-Induced Cardiotoxicity is Mediated in Part via Direct Effects on Cardiac Myocytes and Smooth Muscle Cells Susan M. Dallabrida,Nesreen S. Ismail,Elke Pravda,Flávia Cassiola,Sendia Kim,Emily M. Parodi,Risto Kerkelä,Thomas Force,Mark Puder,Maria A. Rupnick	2007	3
19	Angiopoietin-1 Promotes Cardiac and Skeletal Myocyte Survival Through Integrins Susan M. Dallabrida,Nesreen S. Ismail,J. Oberle,Blanca E. Himes,Maria A. Rupnick	2005	169

About Nesreen S. Ismail

Nesreen S. Ismail is a scholar working on Biotechnology, Cancer Research and Oncology, having authored 19 papers that have together received 1.4k indexed citations. Recurring topics across this work include CAR-T cell therapy research (6 papers), Angiogenesis and VEGF in Cancer (6 papers), Cancer Research and Treatments (5 papers), Cancer, Hypoxia, and Metabolism (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Tissue Engineering and Regenerative Medicine (2 papers), Lipid metabolism and disorders (2 papers) and Immunotherapy and Immune Responses (2 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (611 citations), Oncology (459 citations) and Hematology (114 citations). Nesreen S. Ismail has collaborated with scholars based in United States and Canada. Frequent co-authors include Susan M. Dallabrida, Maria A. Rupnick, Elke Pravda, Flávia Cassiola, David Zurakowski, David M. Harris, Frederick J. Schöen, Jey-Hsin Chen, Risto Kerkelä and Tammy F. Chu.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact